Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome.
Sánchez-Cano
D
D
Callejas-Rubio
J L
JL
Lara-Jiménez
M A
MA
López-Trascasa
M
M
Circadi
M
M
Ortego-Centeno
N
N
D000368:Aged; D000799:Angioedema / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D050718:Complement C1 Inhibitor Protein / Q000032:analysis* / Q000502:physiology; D005260:Female; D006801:Humans; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000150:complications*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D050718:Complement C1 Inhibitor Protein; D000069283:Rituximab